Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Christina N. Mazcko"'
Autor:
Amy K. LeBlanc, Christina N. Mazcko, Timothy M. Fan, David M. Vail, Brian K. Flesner, Jeffrey N. Bryan, Shan Li, Feng Wang, Scott Harris, Jesse D. Vargas, Jeevan P. Govindharajulu, Soumya Jaganathan, Francesca Tomaino, Apurva K. Srivastava, Tsui-Fen Chou, Gordon M. Stott, Joseph M. Covey, Barbara Mroczkowski, James H. Doroshow
Publikováno v:
Mol Cancer Ther
Pet dogs with naturally occurring cancers play an important role in studies of cancer biology and drug development. We assessed tolerability, efficacy, and pharmacokinetic/pharmacodynamic relationships with a first-in-class small molecule inhibitor o
Autor:
James H. Doroshow, Barbara Mroczkowski, Joseph M. Covey, Gordon M. Stott, Tsui-Fen Chou, Apurva K. Srivastava, Francesca Tomaino, Soumya Jaganathan, Jeevan P. Govindharajulu, Jesse D. Vargas, Scott Harris, Feng Wang, Shan Li, Jeffrey N. Bryan, Brian K. Flesner, David M. Vail, Timothy M. Fan, Christina N. Mazcko, Amy K. LeBlanc
Supplementary Data from Comparative Oncology Assessment of a Novel Inhibitor of Valosin-Containing Protein in Tumor-Bearing Dogs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::306d21372321eea9e3620f450a0deeda
https://doi.org/10.1158/1535-7163.22523473.v1
https://doi.org/10.1158/1535-7163.22523473.v1
Autor:
Timothy M. Fan, Chand Khanna, Laura E. Selmic, Daniel L. Gustafson, Sara D. Allstadt, Janean L. Fidel, Michael O. Childress, Kristine Burgess, Antonella Borgatti, Olya Martin, Steven E. Suter, Angela L. McCleary-Wheeler, Cheryl E. Balkman, Lisa G. Barber, Cheryl A. London, Jennifer A. Mahoney, Erika Krick, Raelene M. Wouda, Mary Lynn Higginbotham, Shawna Klahn, Nikolaos Dervisis, Annette N. Smith, Stephanie Lindley, Brandan G. Wustefeld-Janssens, Heather Wilson-Robles, Haley Leeper, Kaitlin M. Curran, Corey Saba, Nicole C. Northrup, J. Paul Woods, Anthony J. Mutsaers, Jennifer L. Willcox, Jenna H. Burton, David M. Vail, Jeffrey N. Bryan, Brian K. Flesner, Kristen Weishaar, Susan E. Lana, Megan E. Brown, William C. Kisseberth, Erika P. Berger, Aswini Cherukuri, Christina N. Mazcko, Amy K. LeBlanc
Supplementary Table 3 contains a summary of the outcomes, with statistical comparisons, of the dogs enrolled in the SOC clinical trial arm. This includes the DFI and outcomes of the groups of dogs stratified by tumor location and ALP status.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cf79f886bb73370f4df3bf2b203861b
https://doi.org/10.1158/1078-0432.22478240
https://doi.org/10.1158/1078-0432.22478240
Autor:
Timothy M. Fan, Chand Khanna, Laura E. Selmic, Daniel L. Gustafson, Sara D. Allstadt, Janean L. Fidel, Michael O. Childress, Kristine Burgess, Antonella Borgatti, Olya Martin, Steven E. Suter, Angela L. McCleary-Wheeler, Cheryl E. Balkman, Lisa G. Barber, Cheryl A. London, Jennifer A. Mahoney, Erika Krick, Raelene M. Wouda, Mary Lynn Higginbotham, Shawna Klahn, Nikolaos Dervisis, Annette N. Smith, Stephanie Lindley, Brandan G. Wustefeld-Janssens, Heather Wilson-Robles, Haley Leeper, Kaitlin M. Curran, Corey Saba, Nicole C. Northrup, J. Paul Woods, Anthony J. Mutsaers, Jennifer L. Willcox, Jenna H. Burton, David M. Vail, Jeffrey N. Bryan, Brian K. Flesner, Kristen Weishaar, Susan E. Lana, Megan E. Brown, William C. Kisseberth, Erika P. Berger, Aswini Cherukuri, Christina N. Mazcko, Amy K. LeBlanc
Supplementary Fig. 1 depicts the chronology of clinical trial visits and associated procedures for dogs enrolled in this clinical trial.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30e206106b269e032e0544bf85a04ba6
https://doi.org/10.1158/1078-0432.22478255
https://doi.org/10.1158/1078-0432.22478255
Autor:
Timothy M. Fan, Chand Khanna, Laura E. Selmic, Daniel L. Gustafson, Sara D. Allstadt, Janean L. Fidel, Michael O. Childress, Kristine Burgess, Antonella Borgatti, Olya Martin, Steven E. Suter, Angela L. McCleary-Wheeler, Cheryl E. Balkman, Lisa G. Barber, Cheryl A. London, Jennifer A. Mahoney, Erika Krick, Raelene M. Wouda, Mary Lynn Higginbotham, Shawna Klahn, Nikolaos Dervisis, Annette N. Smith, Stephanie Lindley, Brandan G. Wustefeld-Janssens, Heather Wilson-Robles, Haley Leeper, Kaitlin M. Curran, Corey Saba, Nicole C. Northrup, J. Paul Woods, Anthony J. Mutsaers, Jennifer L. Willcox, Jenna H. Burton, David M. Vail, Jeffrey N. Bryan, Brian K. Flesner, Kristen Weishaar, Susan E. Lana, Megan E. Brown, William C. Kisseberth, Erika P. Berger, Aswini Cherukuri, Christina N. Mazcko, Amy K. LeBlanc
Supplementary Table 2 contains the summary comparison of both the Intent-to-treat and Per-protocol analyses of clinical outcomes for dogs enrolled in Standard of Care (SOC) and Standard of Care + sirolimus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22720df435a1efb42466d847b634528d
https://doi.org/10.1158/1078-0432.22478243.v1
https://doi.org/10.1158/1078-0432.22478243.v1
Autor:
Timothy M. Fan, Chand Khanna, Laura E. Selmic, Daniel L. Gustafson, Sara D. Allstadt, Janean L. Fidel, Michael O. Childress, Kristine Burgess, Antonella Borgatti, Olya Martin, Steven E. Suter, Angela L. McCleary-Wheeler, Cheryl E. Balkman, Lisa G. Barber, Cheryl A. London, Jennifer A. Mahoney, Erika Krick, Raelene M. Wouda, Mary Lynn Higginbotham, Shawna Klahn, Nikolaos Dervisis, Annette N. Smith, Stephanie Lindley, Brandan G. Wustefeld-Janssens, Heather Wilson-Robles, Haley Leeper, Kaitlin M. Curran, Corey Saba, Nicole C. Northrup, J. Paul Woods, Anthony J. Mutsaers, Jennifer L. Willcox, Jenna H. Burton, David M. Vail, Jeffrey N. Bryan, Brian K. Flesner, Kristen Weishaar, Susan E. Lana, Megan E. Brown, William C. Kisseberth, Erika P. Berger, Aswini Cherukuri, Christina N. Mazcko, Amy K. LeBlanc
Purpose:The mTOR pathway has been identified as a key nutrient signaling hub that participates in metastatic progression of high-grade osteosarcoma. Inhibition of mTOR signaling is biologically achievable with sirolimus, and might slow the outgrowth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84d6627db92e6f7818bf68c257932e98
https://doi.org/10.1158/1078-0432.c.6529898
https://doi.org/10.1158/1078-0432.c.6529898
Autor:
Timothy M. Fan, Chand Khanna, Laura E. Selmic, Daniel L. Gustafson, Sara D. Allstadt, Janean L. Fidel, Michael O. Childress, Kristine Burgess, Antonella Borgatti, Olya Martin, Steven E. Suter, Angela L. McCleary-Wheeler, Cheryl E. Balkman, Lisa G. Barber, Cheryl A. London, Jennifer A. Mahoney, Erika Krick, Raelene M. Wouda, Mary Lynn Higginbotham, Shawna Klahn, Nikolaos Dervisis, Annette N. Smith, Stephanie Lindley, Brandan G. Wustefeld-Janssens, Heather Wilson-Robles, Haley Leeper, Kaitlin M. Curran, Corey Saba, Nicole C. Northrup, J. Paul Woods, Anthony J. Mutsaers, Jennifer L. Willcox, Jenna H. Burton, David M. Vail, Jeffrey N. Bryan, Brian K. Flesner, Kristen Weishaar, Susan E. Lana, Megan E. Brown, William C. Kisseberth, Erika P. Berger, Aswini Cherukuri, Christina N. Mazcko, Amy K. LeBlanc
Supplementary Table 4 contains a summary of the outcomes, with statistical comparisons, of the dogs enrolled in the SOC + sirolimus clinical trial arm. This includes the DFI and outcomes of the groups of dogs stratified by tumor location and ALP stat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12b4b2bcfb3ae31f8ee4ca6faffb8b03
https://doi.org/10.1158/1078-0432.22478234.v1
https://doi.org/10.1158/1078-0432.22478234.v1
Autor:
Timothy M. Fan, Chand Khanna, Laura E. Selmic, Daniel L. Gustafson, Sara D. Allstadt, Janean L. Fidel, Michael O. Childress, Kristine Burgess, Antonella Borgatti, Olya Martin, Steven E. Suter, Angela L. McCleary-Wheeler, Cheryl E. Balkman, Lisa G. Barber, Cheryl A. London, Jennifer A. Mahoney, Erika Krick, Raelene M. Wouda, Mary Lynn Higginbotham, Shawna Klahn, Nikolaos Dervisis, Annette N. Smith, Stephanie Lindley, Brandan G. Wustefeld-Janssens, Heather Wilson-Robles, Haley Leeper, Kaitlin M. Curran, Corey Saba, Nicole C. Northrup, J. Paul Woods, Anthony J. Mutsaers, Jennifer L. Willcox, Jenna H. Burton, David M. Vail, Jeffrey N. Bryan, Brian K. Flesner, Kristen Weishaar, Susan E. Lana, Megan E. Brown, William C. Kisseberth, Erika P. Berger, Aswini Cherukuri, Christina N. Mazcko, Amy K. LeBlanc
Supplementary Table 1 contains the inclusion and exclusion criteria for pet dogs considered for enrollment into the SOC and SOC + S clinical trial arms.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c8771cb32678faca85f7857e9bfb82e
https://doi.org/10.1158/1078-0432.22478246.v1
https://doi.org/10.1158/1078-0432.22478246.v1
Autor:
Timothy M. Fan, Chand Khanna, Laura E. Selmic, Daniel L. Gustafson, Sara D. Allstadt, Janean L. Fidel, Michael O. Childress, Kristine Burgess, Antonella Borgatti, Olya Martin, Steven E. Suter, Angela L. McCleary-Wheeler, Cheryl E. Balkman, Lisa G. Barber, Cheryl A. London, Jennifer A. Mahoney, Erika Krick, Raelene M. Wouda, Mary Lynn Higginbotham, Shawna Klahn, Nikolaos Dervisis, Annette N. Smith, Stephanie Lindley, Brandan G. Wustefeld-Janssens, Heather Wilson-Robles, Haley Leeper, Kaitlin M. Curran, Corey Saba, Nicole C. Northrup, J. Paul Woods, Anthony J. Mutsaers, Jennifer L. Willcox, Jenna H. Burton, David M. Vail, Jeffrey N. Bryan, Brian K. Flesner, Kristen Weishaar, Susan E. Lana, Megan E. Brown, William C. Kisseberth, Erika P. Berger, Aswini Cherukuri, Christina N. Mazcko, Amy K. LeBlanc
Supplementary Fig. 2 shows the walk-in pharmacokinetics, both measured results and simulated values, for dogs treated with oral sirolimus in preparation for the definitive adjuvant trial.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0edbd37a95c6642ae6a32b8a9bce281c
https://doi.org/10.1158/1078-0432.22478252
https://doi.org/10.1158/1078-0432.22478252
Autor:
Amy K, LeBlanc, Christina N, Mazcko
Publikováno v:
Nature reviews. Cancer. 20(12)
Comparative oncology clinical trials play an important and growing role in cancer research and drug development efforts. These trials, typically conducted in companion (pet) dogs, allow assessment of novel anticancer agents and combination therapies